Demeetra AgBio, Inc.

Cas-CLOVER Gene Editing of HEK293 Cells: A Better Investment Than CRISPR For Commercial Gene Therapy and Vaccine Bioprocessing

By Demeetra AgBio, Inc. / December 3, 2021

Viruses equipt with natural abilities as vehicles of gene transfer, promote host-viral co-evolution. For millions of years, the human immune system has been at war with all types of viruses and pathogens, resulting in new serotypes and mechanisms of gene transfer. Humans have complex immune systems and are able to ward off some of them,…

Read More
“The Hipp11 gene is a safe harbor locus for gene knock-in” (500 x 350)

Increasing Efficiencies in Bioprocessing with Cas-CLOVER

By Demeetra AgBio, Inc. / November 11, 2021

There are multiple mammalian cell expression systems used in the production of biotherapeutic proteins. However, development of recombinant mammalian cell lines is often delayed because of the unstable and variable transgene expression associated with random integration. To remedy this common gap in research, Demeetra has developed an efficient strategy for site-specific integration of one or…

Read More

ROI of using Cas-CLOVER vs. CRISPR/Cas9 in cell line development for commercial therapeutic bioprocessing

By Demeetra AgBio, Inc. / November 11, 2021

Cell line development (CLD), the process of engineering a cell line to manufacture human biologic therapeutics, has harnessed a multitude of technological advancements over the past few years. Traditional methods of gene transfection for biologics production are considered expensive, time-consuming, and riddled with unstable expressions. The CRISPR/Cas9 system completely changed the CLD landscape with targeted…

Read More
Demeetra - Blog - Glyco-Engineering of Yeasts for Biotherapeutics Production Using piggyBac

Glyco-Engineering of Yeasts for Biotherapeutics Production Using piggyBac

By Demeetra AgBio, Inc. / November 11, 2021

As many already know, recombinant therapeutic proteins are becoming an integral part of treating an array of conditions from cancer to autoimmune diseases. Almost all of the therapeutic proteins produced today are currently in mammalian cells. However, many other therapeutic protein expression systems exist, such as bacterial, insect, plant, and yeast. Yeasts have multiple advantages…

Read More
dart board and text “Use Cas-CLOVER for cleaner editing” (1370 x 1024)

Cas-CLOVER Continues to Show Fewer Off-Target Mutations than CRISPR/Cas9

By Demeetra AgBio, Inc. / November 11, 2021

Using unbiased analysis Cas-CLOVER’s maximum potential off-target is under 1% where CRISPR/Cas9 is 5-13%. Two off-target analyses have recently been performed with Cas-CLOVER which resemble similar findings in previous research that prove it’s an exceptional alternative to the CRISPR/Cas9 platform. Cas-CLOVER is a cleaner gene editing alternative to CRISPR/Cas9 for research and in particular commercial…

Read More
man wearing blue jacket; text “CRISPR MEDICINE NEWS INTERVIEW WITH DEMEETRA AGBIO CEO, JACK CRAWFORD”

CRISPR Medicine News Interview with Demeetra AgBio CEO, Jack Crawford

By Demeetra AgBio, Inc. / November 11, 2021

Demeetra AgBio, headquartered in Kentucky, is pioneering a unique genome-editing technology called Cas-CLOVER. Applications include plant-based drug development, enhanced bioprocessing for human and animal health, and engineering of crops and agricultural animals for improved traits. We spoke with Demeetra’s CEO Jack Crawford to hear more about Cas-CLOVER and its potential within human health and medicine.…

Read More

Genetic Scissors, Demeetra AgBio Offers Tobacco Companies a New Tool to Reduce Nicotine Levels

By Demeetra AgBio, Inc. / August 6, 2021

The goal of making combustible cigarettes less addictive by removing or significantly lowering their nicotine content to minimally or nonaddictive levels has long been on the U.S. Food and Drug Administration’s agenda. In July 2017, the agency announced a plan that became part of its multi-year roadmap for tobacco and nicotine regulation. When the FDA…

Read More

As FDA considers Cutting Nicotine in Cigarettes, Demeetra AgBio Announces It Can Produce Harm-Reduced Tobacco Products Through Gene Editing

By Demeetra AgBio, Inc. / June 21, 2021

Precision gene editing in tobacco is being applied to harm-reduced nicotine product manufacturing LEXINGTON, Ky., June 15, 2021 /PRNewswire/ — Amid the FDA’s confirmation it is considering a global reduction on nicotine in cigarettes to non- addictive levels, Demeetra AgBio, Inc., a pre-clinical therapeutics development, agbio, and genetic engineering company, announced today that its proprietary…

Read More

Demeetra AgBio Advances Major Pipeline for Therapeutic Cannabinoid Development; Invites Collaborations

By Demeetra AgBio, Inc. / June 21, 2021

The company is building a platform to achieve unlimited cannabis bioproduct candidates by combining proprietary gene editing, synthetic biotechnology, and optimized drug development processes. LEXINGTON, Ky., June 16, 2021 /PRNewswire/ — Demeetra AgBio, Inc., a pre-clinical therapeutics development and genetic engineering company, announced that it is advancing a broad pipeline for therapeutic cannabinoids and expects to file an…

Read More

piggyBac’s Massive DNA Cargo-Carrying Capacity Simplifies and Enhances The Bioproduction of High Value Metabolites

By Demeetra AgBio, Inc. / June 18, 2021

Using a single ~29kb vector, Demeetra’s proprietary piggyBac DNA Modification System introduces the entire mevalonate pathway, a key component for cannabinoid manufacturing in s. cerevisiae. This approach can be applied to any pathway in any yeast strain without preconceived knowledge of the target site for homologous recombination. From industrial biotechnology to agriculture and beyond, the…

Read More